istock-1030818812_artisteer

artisteer / iStockphoto.com

22 October 2018Biotechnology

Gene-editing: a block on further development

In late July, Europe’s highest court handed down a much-awaited ruling on gene-editing which was met by an uproar from parts of the scientific community.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Broad Institute wins appeal to restore CRISPR patent in Europe

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations

Regeneron hits Amgen over its blockbuster eye disease treatment

Diverging in the detail: UPC local divisions and Court of Appeal take different paths